Association Between Impairment of DNA Double Strand Break Repair and Decreased Ovarian Reserve in Patients With Endometriosis by 源��쁽�닔 et al.
ORIGINAL RESEARCH
published: 21 December 2018
doi: 10.3389/fendo.2018.00772
Frontiers in Endocrinology | www.frontiersin.org 1 December 2018 | Volume 9 | Article 772
Edited by:
Jung Ryeol Lee,
Seoul National University College of
Medicine, South Korea
Reviewed by:
Jung-ho Shin,
Korea University, South Korea
Giuliano Marchetti Bedoschi,
University of São Paulo, Brazil
*Correspondence:
Hyun-Soo Kim
hyunsookim@yuhs.ac
SiHyun Cho
sihyuncho@yuhs.ac
Specialty section:
This article was submitted to
Reproduction,
a section of the journal
Frontiers in Endocrinology
Received: 30 October 2018
Accepted: 10 December 2018
Published: 21 December 2018
Citation:
Choi YS, Park JH, Lee JH, Yoon J-K,
Yun BH, Park JH, Seo SK, Sung H-J,
Kim H-S, Cho S and Lee BS (2018)
Association Between Impairment of
DNA Double Strand Break Repair and
Decreased Ovarian Reserve in
Patients With Endometriosis.
Front. Endocrinol. 9:772.
doi: 10.3389/fendo.2018.00772
Association Between Impairment of
DNA Double Strand Break Repair and
Decreased Ovarian Reserve in
Patients With Endometriosis
Young Sik Choi 1,2, Ji Hyun Park 2,3, Jae Hoon Lee 1,2, Jeong-Kee Yoon 4, Bo Hyon Yun 1,2,
Joo Hyun Park 2,3, Seok Kyo Seo 1,2, Hak-Joon Sung 4, Hyun-Soo Kim 5*, SiHyun Cho 2,3* and
Byung Seok Lee 1,2
1Department of Obstetrics and Gynecology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea,
2 Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Seoul, South Korea, 3Department of
Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea,
4Department of Medical Engineering, Yonsei University College of Medicine, Seoul, South Korea, 5Department of Pathology,
Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
Background: Repair of DNA double strand break (DSB) is an important mechanism
for maintaining genetic stability during a DNA damage event. Although, a growing body
of recent evidence suggests that DNA DSBs and related repair mechanisms may be
important in ovarian aging and in various cancers, there are few reports in endometriosis.
We, therefore, examined expression levels of genes pertaining to DNA DSB repair in
patients with endometriosis to assess the potential effects on ovarian reserves.
Materials and methods: A total of 69 women undergoing laparoscopic surgery
for endometriosis and other benign conditions was included; endometriosis group (n
= 38) vs. controls (n = 31). DNA DSBs in endometrial and ovarian tissues of both
groups were compared via immunohistochemistry, aimed at γ-H2AX expression. To
gauge genotoxin-induced DNA DSBs in endometrial stromal cells, γ-H2AX expression
was determined by western blot after H2O2 treatment of cultured endometrial stromal
cells (endometriosis group and controls) and Ishikawa cell-line cultures. Endometrial and
ovarian tissue levels of BRCA1, BRCA2, Rad51, and ATM (ataxia-telangiectasia mutated)
mRNA expression were also compared. Correlations between expression levels of genes
of interest and serum anti-müllerian hormone (AMH) levels were assessed as well.
Results: Expression of γ-H2AX in immunostained endometrial and ovarian tissue
preparations was greater in the endometriosis group, comparedwith controls. After H2O2
treatment, γ-H2AX expression levels were also significantly greater in cultured stromal
cells of the endometriosis group and in the Ishikawa cell line than in controls. Endometrial
expression of BRCA1 and Rad51 mRNA proved significantly lower in the endometriosis
group (vs. controls), as did ovarian expression ofBRCA1 andBRCA2mRNA. SerumAMH
concentration showed a significant correlation with ovarian BRCA1 mRNA expression in
women with endometriosis (p = 0.03).
Conclusions: In women with endometriosis, expression levels of various genes
implicated in DSB repair are decreased and ovarian BRCA1 expression correlates with
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ovarian reserves. These findings indicate that impaired DSB repair may contribute to
diminished ovarian reserves in this setting.
Keywords: endometriosis, ovarian reserve, double stranded DNA break, BRCA1 gene, gamma-H2AX
INTRODUCTION
Endometriosis is characterized by the presence of endometrium-
like epithelium and stroma outside the endometrium and
myometrium (1), and not necessarily restricted to the pelvic
compartment. This disease is one of the most common
gynecologic disorders affecting ∼10% of all reproductive-age
women and 20–50% of women with chronic pelvic pain and/or
infertility (2).
The biologic mechanisms that may link endometriosis and
subfertility have not been fully explained. However, several
mechanisms (e.g., pelvic adhesions, altered peritoneal, hormonal,
or cell-mediated function, abnormal cytokine release, endocrine
and ovulatory abnormalities, and impaired implantation) have
been proposed (3). Studies from oocyte donation–in vitro
fertilization and embryo transfer, which may exclude the
impact of endometrial receptivity, suggest that subfertility in
endometriosis is attributed to quality of oocytes rather than
endometrial receptivity (4). In addition to the qualitative issues
of oocytes, quantitative declines in ovarian reserve are also
of concern for women with endometriosis (5). The impact
of minimal-to-mild endometriosis on ovarian reserves has
seemed inconsistent, but it is speculated that advanced-stage
endometriosis may be detrimental in this regard, regardless
of any surgical damage. As serum anti-Müllerian hormone
(AMH) concentrations and antral follicle counts (AFCs)
confirm, endometriomas per se are associated with diminished
ovarian reserves (6, 7); and endometriosis or endometriomas
may impact responsiveness to controlled ovarian stimulation,
reflected by numbers of oocytes collected (8). Thus, declining
ovarian reserves appear directly related to endometriosis.
Such deterioration due to both pathologic underpinnings of
endometriosis and any surgical damage incurred is the source
of mounting attention on fertility preservation in women with
endometriosis (5, 9).
At present, however, the pathophysiologic mechanisms of
diminished ovarian reserves in endometriosis remain unclear.
Tissues bordering endometriomas often show morphologic
alterations (i.e., substantial loss of cortical stroma, fibrosis, and
considerably less follicular density) that are not present near
other benign cysts (10, 11). Similar pathologic changes, including
focal fibrosis and vascular deficiency, have likewise been observed
in ovarian cortex exposed to chemotherapy (12). The proportion
of primordial follicles present in ovaries with endometriomas is
distinctly lower by comparison, and there are notable increases
in proportions of non-resting growing follicles (13). This
“burn-out” effect on follicular reservoirs is also suggested as
a major mechanism leading to chemotherapy-induced loss of
ovarian reserves (14, 15). Hence, patients with endometriosis
may follow a path similar to chemotherapy-induced ovarian
damage.
Cells sustain DNA damage through both external and internal
means. Among the various types of DNA damage due to
environmental genotoxins, DNA double-strand breaks (DSBs)
are capable of substantially altering genetic integrity and thus are
the most deleterious. The ataxia-telangiectasia mutated (ATM)–
mediated DNA damage signaling (DDS) pathway regulates repair
of DNA DSBs via a homologous recombination mechanism.
In instances of irreparable DNA damage, cells are eliminated
by apoptotic cell death or undergo senescence (complete cell-
cycle withdrawal) to avoid severe mutagenic consequences (16).
Impaired DNA DSB repair may be associated with loss of
ovarian follicular reserves, BRCA1, and other key genes in
the ATM pathway that decline with age in human oocytes
(17). Furthermore, chemotherapy causes massive DNA DSBs in
primordial follicles, oocytes, and granulosa cells. Such damage
is associated with apoptotic oocyte death, which then triggers
the DNA repair response by activating the ATM-medicated DDS
pathway (18, 19).
It has been suggested that endometriosis per se affects ovarian
reserve. Although evidence of an association between DNADSBs
and ovarian reserves has emerged, there has been no pertinent
data on women with endometriosis. Considering that it was
reported that morphologic changes in ovary of women with
endometriosis were similar to those after chemotherapy-induced
ovarian damage, we hypothesized that diminished ovarian
reserve in women with endometriosis may have similar pathway
to chemotherapy-induced ovarian damage (e.g., increased DNA
damage and impaired repair mechanism). In the present study,
we assessed the extent of genotoxin-induced DNA damage to
in vitro cultures of endometrial stromal cells. We also used
endometrial and ovarian tissues of women with endometriosis
to investigate DNA damage and expression levels of genes
implicated in DNA DSB repair in an effort to determine the
ramifications for ovarian reserves.
MATERIALS AND METHODS
Study Population and Sample Collection
Among candidates undergoing laparoscopic surgery for various
indications (e.g., pelvic masses or pain, endometriosis, infertility,
and diagnostic evaluations of benign gynecologic diseases)
from January 2015 to September 2017, only those aged 25–
40 years with a body mass index (BMI) of 18.5–29.9 kg/m2
were included in this prospective case-control study after
granting written informed consent. The present study was
performed in university research center and approved by the
Institutional Review Board of Gangnam Severance Hospital
(IRB number 3-2015-0250). Postmenopausal status, previous
use of a hormone or a gonadotropin-releasing hormone
(GnRH) agonist within 6 months, prior ovarian surgery, or
other medical disorders (including adenomyosis; endometrial
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hyperplasia, polyps, or cancer; infectious diseases; chronic
or acute inflammatory diseases; malignancies; autoimmune
diseases; or cardiovascular diseases) were grounds for study
exclusion.
At the time of surgery, all possible endometriotic lesions
were excised and sent for pathologic examination to confirm
the diagnosis. Patients were assigned to the endometriosis
group only after pathologic confirmation of the excised
tissue. The extent of endometriosis was determined using the
American Society of Reproductive Medicine (ASRM) revised
classification (20). Overall, 38 patients displayed moderate-
to-severe endometriosis (stages III and IV), histologically
confirmed. Another 31 patients were confirmed that they
had no endometriosis by laparoscopy and served as controls.
They were diagnosed with the following ovarian neoplasms:
dermoid cyst (n = 20), serous cystadenoma (n = 6),
and mucinous cystadenoma (n = 5). Endometrial samples
were collected from the patients by Pipelle sampler (Cooper
Surgical, Trumbull, CT, USA) during surgery irrespective of
menstrual phase. Tweleve out of 38 patients (31.5%) in the
endometriosis group and 9 out of 31 patients (29.0%) in the
controls were in proliferative phase and others in secretory
phase.
Main outcomes were γ-H2AX protein expression, mRNA
expression of BRCA1, BRCA2, and Rad51, and ATM in eutopic
endometrium and ovarian tissue, γ-H2AX protein expression
of cultured endometrial stomal cells after H2O2 treatment, and
correlation between DNA DSB repair genes of interest and
AMH.
Immunohistochemistry
Immunohistochemical staining was performed in five
participants of each group. γ-H2AX protein expression was
assessed by ready-to-use immunostain application (Bond
Polymer Intense Detection System; Vision BioSystems, Wetzlar,
Germany) following the manufacturer’s instructions. Surgically
resected tissues were first fixed in 10% neutral buffered formalin
for 12–24 h. Samples were then selected for routine processing
(in automated system), embedding in paraffin, and slide
preparation, sectioning at 4µm by rotary microtome. Once
deparaffinized (Bond Dewax Solution; Vision BioSystems),
antigen retrieval proceeded (Bond Epitope Retrieval Solution;
Vision BioSystems) by treating sections for 30min at 100◦C.
Endogenous peroxidases were quenched by a 5-min hydrogen
peroxide pretreatment. Sections were then incubated for 15min
at ambient temperature with rabbit polyclonal γ-H2AX antibody
(1:500 dilution; Bethyl Laboratories, Montgomery, TX, USA). A
biotin-free polymeric horseradish peroxidase-linked antibody
conjugate system was finally applied (BOND-MAX automatic
slide stainer; Vision BioSystems), and sections were developed
using 1mM 3,3
′
-diaminobenzidine as the chromogen, 50mM
Tris-hydrogen chloride buffer (pH 7.6), and 0.006% hydrogen
peroxide, with hematoxylin as counterstain. Positive (breast
cancer tissue), and negative control slides were generated for
each reaction to minimize inter-assay variation. For the negative
controls, the primary antibody was replaced by non-immune
serum to yield no detectable γ-H2AX staining.
Culture of Primary Endometrial Stromal
Cells and Ishikawa Cell Lines
Since Ishikawa cell line, a well-differentiated human endometrial
adenocarcinoma cell line bears estrogen and progesterone
receptors, the cells have been used numerous basic research areas
such as reproductive biology and molecular science including
endometriosis researches (21). Since it was also suggested that
genotoxic exposure such as chemotherapeutic agent induced
substantial increase in gamma-H2AX in Ishikawa cell lines (22),
these cell lines were used as a positive control to quantify DNA
damage in in vitro cell culture study. Eutopic endometrium
of women with endometriosis shows fundamental differences
compared with that of healthy control (23). Since, therefore,
eutopic endometrial stromal cells of women with endometriosis
may have altered responses to genotoxic exposure, in vitro
cell culture study was performed to compare the extent of
DNA damage following genotoxic stimuli between endometrial
stromal cells obtained from endometriosis group and controls.
We utilized a previously published method to culture
endometrial stromal cells (24). Endometrium was finely
minced, and the cells were dispersed by incubation at 37◦C
for 60min with agitation while adding (pipetting) Hanks
balanced salt solution (HBSS) containing 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES; 2 mmol/mL),
penicillin/streptomycin (1%), and collagenase (1 mg/mL,
15 U/mg). The cells were pelleted, washed, suspended in
Ham’s F12:Dulbecco’s Modified Eagle Medium (DMEM) in
a 1:1 ratio containing 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin, passed through a 40-µm cell strainer
(Falcon, Corning, NY, USA), and plated onto 75-cm2 Falcon
tissue culture flasks (BD Biosciences, Bedford, MA, USA).
Cultured primary human endometrial stromal cells (HESCs)
at passages 3–5 were used for analysis. Ishikawa cells were
maintained inMEM (Invitrogen, Carlsbad, CA, USA) containing
2.0 mmol/L l-glutamine and Earl’s Salts, supplemented with
10% FBS, 1% sodium pyruvate, and 1% penicillin/streptomycin.
HESCs from patients with endometriosis and Ishikawa cells were
harvested from culture flasks using trypsin/EDTA (0.05%). The
cells were then counted (5 × 106) for plating in six-well plates
at 37◦C in a 5% CO2 humidified environment and grown as
previously described. At 80% confluency, the cells were treated
with 250 µmol/L H2O2 concentrations, extracting proteins 4 h
later. In vitro cell culture experiments were triplicated.
RNA Extraction and Quantitative Real-Time
Polymerase Chain Reaction (RT-PCR)
Endometrial samples of all participants were analyzed by
quantitative RT-PCR. Total RNA was extracted using a kit
(RNeasy Mini; Qiagen, Valencia, CA, USA). A total of 2 µg
RNA from each sample was reverse transcribed into cDNA
(SuperScript III First-Strand Synthesis System; Invitrogen), all
according to manufacturer protocols. Expression of candidate
gene mRNA was measured by SYBR RT PCR on an ABI
7300 instrument (Applied Biosystems, Forster, CA, USA). We
designed specific primers for BRCA1 (forward primer 5
′
-AG
CTGTGTGGTGCTTCTGTGGT-3
′
, reverse primer 5
′
-TGG
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CTGCACAACCACAATTGGG-3
′
), BRCA2 (forward primer
5
′
-CTTGCTTTCAAATTGGCACTGA-3
′
, reverse primer
5
′
-GTTTAAAAGGGCATAGGCT CTG-3
′
), Rad51 (forward
primer 5
′
-TAGC AAAGGGAATGGGT CTGC-3
′
, reverse
primer 5
′
-GCACAAGACTCCATAACCAAAC-3
′
), and ATM
(forward primer 5
′
-GCTCAGTGTTGGTGGACAGGT-3
′
,
reverse primer 5
′
-TCCATCCTGGGAAAAGTCG GCT-3
′
). The
PCR reaction was performed in 20 µL buffer containing 2 µL of
cDNA, 5 pM each primer, and power SYBR green PCR master
mix (Applied Biosystems). The thermal cycling conditions were
pre-incubated for 2min at 50◦C, then denatured for 10min at
95◦C, followed by 40 cycles of denaturation for 15 s at 95◦C, and
annealing and extension for 1min at 60◦C. To normalize the
amount of total RNA present in each reaction, we amplified the
housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase
(GADPH). Sequences for GAPDH were as follows: forward
primer 5
′
-GAAGGT GAAGGTCGGAGTC-3
′
and reverse
primer 5
′
-GAAGATGGTGATGGGATTTC-3
′
. The amount
of target, which was normalized to the endogenous reference
(GAPDH) and was compared to the calibrator, was defined by the
11CT method, as previously described (25). Endometrial tissue
contributed by a normal patient was used as the calibrator in
the following normalization formula: target amount = 2−11Ct,
where11Ct= [Ct (target gene sample) – Ct (GAPDH sample)]
– [Ct (target gene calibrator) – Ct (GAPDH calibrator)]. The
latter was calculated by Light Cycler v4.0 software.
Protein Extraction and Western Blot
Analysis
Protein extracts were prepared using RIPA buffer (Thermo
Scientific, Rockford, IL, USA) containing freshly added
protease and phosphatase inhibitor cocktail (Thermo Scientific).
Concentrations of total cell lysates were measured using BCA
protein assay kit (Thermo Scientific). Altogether, 30 µg of total
protein were mixed with 5 × sample buffer and heated at 95◦C
for 5min. The samples were loaded onto 12% sodium dodecyl
sulfate-polyacrylamide gels (SDS-PAGE) and electrotransferred
to polyvinylidene fluoride membranes (Millipore Corp, Billerica,
MA, USA) using a Trans-Blot apparatus (Bio-Rad, Hercules,
CA, USA). The membranes were blocked using 5% non-fat
skim milk in Tris-buffered saline solution [10 mmol/L Tris-
HCl (pH 7.4) and 0.5 mol/L NaCl), adding Tween-20 (0.1%
vol/vol]. Blots were probed using primary antibodies to γ-H2AX
(1:2,000; Bethyl Laboratories) and GAPDH (1:5,000; Santa
Cruz Biotechnology, Dallas, TX, USA), followed by horseradish
peroxidase-conjugated secondary anti-mouse (1:6,000; Thermo
Scientific) or anti-rabbit antibody (1:5,000; Thermo Scientific).
Protein detection was achieved by enhanced chemiluminescence
(Santa Cruz Biotechnology). The experiment was performed in
triplicate for analyses, all data shown being representative.
Immunofluorescence Staining
Immunofluorescence staining of BRCA1 was performed in five
participants of each group. Selected cells on glass coverslips
were fixed in cold acetone for 10min, incubated with 1%
BSA/PBS for 10min, and then stained using mouse anti-BRCA1
monoclonal antibody as primary antibody (sc-135732; Santa
TABLE 1 | Clinical characteristics of study participants with and
without endometriosis.
EMS (n = 38) Control (n = 31) p-value
Age (years) 35.02 ± 1.22 36.64 ± 1.18 0.353
Gravidity 1.13 ± 0.23 2.16 ± 0.31 0.009
Parity 0.64 ± 0.15 1.35 ± 0.17 0.003
BMI (kg/m2) 20.47 ± 0.30 22.39 ± 0.44 <0.001
CA-125 (U/mL) 65.27 ± 8.28 19.03 ± 2.59 <0.001
EMS STAGE
III 18 (47.4%) N/A
IV 20 (52.6%)
rAFS scores 49.22 ± 25.57 N/A
Serum AMH (ng/mL) 2.05 ± 0.40 4.97 ± 1.18 0.039
Data expressed as mean ± standard error mean (SEM) BMI, body mass index; EMS,
endometriosis; rAFS, revised American Fertility Society; AMH, anti-Müllerian hormone.
Cruz Biotechnology) and goat anti-mouse secondary antibody
conjugated with Cy3 (Abcam, Cambridge, UK). Fluorescence
images from the slides were viewed and captured using a
LSM510 microscope (ZEISS, Jena, Germany) and processed
using proprietary LSM image software.
Statistical Analysis
The sample size was calculated to compare mRNA expression
of genes related to DNA DSB repair between two groups. A
power calculation was performed using PS Power and Sample
Size Calculations (Version 3.1.2). Power analysis showed that
at least 30 patients would be needed to detect a 30% difference
with a significance level of 0.05 and 80% power. Considering 10%
drop-out rate, the sample size required per group was 33.
All data (expressed as mean ± SEM) were subjected to
Kolmogorov-Smirnov or Shapiro-Wilk test to check for normal
distribution and compared using Student’s t-test or Mann-
Whitney U-test, as appropriate. Correlations between ovarian
BRCA mRNA expression and serum AMH levels were assessed
using Spearman’s correlation coefficient. All computations relied
on standard software (SPSS v16.0; SPSS Inc, Chicago, IL, USA),
setting statistical significance at p< 0.05.
RESULTS
Clinical Characteristics
The endometriosis group and controls did not differ significantly
in terms of age. However, controls significantly surpassed
endometriosis group members in gravidity (2.16 ± 0.31 vs. 1.13
± 0.23; p = 0.009) and parity (1.35 ± 0.17 vs. 0.63 ± 0.15;
p = 0.003); and serum CA 125 levels were significantly higher
in the endometriosis group than in controls (19.03 ± 2.59 vs.
65.27 ± 8.28; p < 0.001). BMI was significantly lower in the
endometriosis group than in controls (20.47 ± 0.30 vs. 22.39
± 0.44; p < 0.001). All patients in the endometriosis group
had advanced-stage endometriosis, showing a mean revised AFS
score of 49.22 ± 25.57. Serum AMH levels were significantly
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FIGURE 1 | Expression levels of γ-H2AX protein in tissue samples of eutopic and ectopic endometrium of patients with and without endometriosis. (A) CTL-EM,
eutopic endometrium of control group: γ-H2AX expression absent, or very faint in stromal cells; (B) EMS-EM, ectopic endometrium of endometriosis group: patchy
γ-H2AX expression of variable staining intensity, most stromal cells showing moderate nuclear γ-H2AX immunoreactivity; (C) EMS-OV, ectopic endometrium of
endometriosis group: stromal cells demonstrating uniform and strong γ-H2AX immunoreactivity (γ-H2AX expression by glandular epithelium similar in control and in
endometriosis groups); and (D) CTL-OV, normal ovarian stroma: absence of γ-H2AX expression (original magnification: A–D, × 100; inset, × 400).
lower in the endometriosis group, compared with controls (2.05
± 0.40 vs. 4.97± 1.18; p= 0.039) (Table 1).
Immunohistochemical Staining of γ-H2AX
We evaluated γ-H2AX protein expression in eutopic and ectopic
endometrial tissues of patients with or without endometriosis
in immunostained tissue sections. Representative images γ-
H2AX immunoreactivities are shown in Figure 1. In eutopic
endometrial tissue of the control group, γ-H2AX expression was
absent or faint in nuclei of stromal cells (Figure 1A); whereas
most stromal cells in eutopic endometrium of patients with
endometriosis showed moderate nuclear γ-H2AX expression
(Figure 1B), and some stromal cells showed faint cytoplasmic
γ-H2AX positivity. In a sample of ovarian endometrioma, γ-
H2AX expression was clearly increased, compared with eutopic
endometrial tissues. Uniform and strong nuclear γ-H2AX
expression was also observed in ectopic endometrium of patients
with endometriosis (Figure 1C). In normal ovarian stroma, no
γ-H2AX expression was evident (Figure 1D). No between-group
difference in glandular expression of γ-H2AX was observed.
Western Blot Analysis of γ-H2AX
Expression After H2O2 Treatment of
Cultured Endometrial Stromal Cells and
Ishikawa Cell Lines
After H2O2 treatment of cultured Ishikawa cell lines and
endometrial stromal cells from patients with endometriosis and
controls, γ-H2AX expression as a marker of DNA DSB was
measured by western blot (Figure 2). Post-treatment γ-H2AX
expression levels in Ishikawa cells and endometrial stromal
cells of patients with endometriosis patients were significantly
elevated, compared with pretreatment levels [relative γ-H2AX
expression/GAPDH: 0.88 ± 0.25 vs. 5.03 ± 1.02 (p = 0.049) and
1.00 ± 0.15 vs. 2.02 ± 0.26 (p = 0.016), respectively]. However,
no γ-H2AX expression was evident in endometrial stromal cells
of controls, despite observed H2O2 treatment (relative γ-H2AX
expression/GAPDH: 1.07± 0.15 vs. 0.86± 0.11; p= 0.32).
Expression Levels of BRCA1, BRCA2,
Rad51, and ATM mRNA in Endometriosis
Group and Controls
Endometrial and ovarian expression levels of BRCA1, BRCA2,
Rad51, and ATM mRNA in the endometriosis group and in
controls are shown in Figures 3, 4. Although endometrial BRCA2
mRNA expression was comparable in both groups (2.19 ± 0.59
vs. 9.86 ± 3.02; p = 0.051), levels of BRCA1, Rad51, and ATM
were significantly lower in endometriosis group, compared with
controls [0.25 ± 0.03 vs. 0.54 ± 0.11 (p = 0.014); 4.95 ± 1.11 vs.
11.77 ± 3.05 (p = 0.024); and 0.25 ± 0.03 vs. 0.545 ± 0.11 (p =
0.016), respectively]. Ovarian expression of BRCA1 and BRCA2
was significantly lower in the endometriosis group, compared
with controls [0.12 ± 0.06 vs. 0.22 ± 0.09 (p = 0.045) and 0.16
± 0.08 vs. 1.26 ± 0.52 (p = 0.001), respectively]; but Rad51 and
ATM expression levels were comparable in the two groups [0.38
± 0.11 vs. 0.51± 0.16 (p= 0.621) and 0.79± 0.13 vs. 0.76± 0.26
(p= 0.526), respectively].
Serum AMH concentration and ovarian BRCA1 mRNA
expression correlated significantly in the endometriosis group
(correlation coefficient, 0.541; p= 0.03) (Figure 5).
Immunofluorescence Staining of BRCA1
Decreased expression of BRCA1 protein in endometrial and
ovarian tissues of the endometriosis group was confirmed by
immunofluorescence staining (Figure 6).
DISCUSSION
In the present study, we have demonstrated that mRNA
expression levels for key genes related to DSB repair are reduced
in women with endometriosis. Indeed, expression levels of
BRCA1, Rad51, and ATM in endometrial tissue proved to be
lower in the endometriosis group than in control subjects, as
were expression levels of BRCA1 and BRCA2 in ovarian tissue.
Ovarian BRCA1 expression in particular correlated with serum
AMH levels as a marker of ovarian reserves. To our knowledge,
this is the first study to evaluate the role of impaired DNA DSB
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FIGURE 2 | Western blot analysis of γ-H2AX in cultured Ishikawa cell lines and in primary endometrial stromal cells of patients with and without endometriosis after
H2O2 treatment. *p < 0.05. Data are expressed as mean ± SEM values. +, with H2O2 treatment; –, without H2O2 treatment; CTL-EM, eutopic endometrium of
patients without endometriosis; EMS-EM, eutopic endometrium of patients with endometriosis.
repair in the pathogenic declines of ovarian reserves experienced
by women with endometriosis.
Above findings are aligned with previous studies of
diminished ovarian reserves in women with BRCA mutations.
Women with germline mutations of the BRCA1 gene showed
low responses to controlled ovarian stimulation for fertility
preservation by oocyte or embryo cryopreservation (26) and had
lower age- and BMI- adjusted serum AMH levels, indicating
that BRCA1mutations may be associated with decreased ovarian
reserves. Furthermore, women with BRCA1 mutations may
also be associated with earlier menopause (27, 28). In a recent
comparative study of ovarian tissue obtained from unaffected
BRCA mutation carriers and age-matched cadaveric organ
donors, BRCA mutations were associated with reduced ovarian
reserves as well as accelerated loss of primordial follicle and
oocyte DNA damage (29). These observations support that
DNA DSB repair plays an important role in maintaining ovarian
reserve and suggest that such reserves are prematurely depleted
in women with BRCA1mutations.
Apart from BRCA1/2 germline mutations, other BRCA
defects (including methylation of the BRCA1 promoter, low-
level expression, and copy-number deletions) in some sporadic
cancers share phenotypic traits of tumors that carry BRCA1/2
mutations (30). BRCA1/2 mRNA expression levels have been
previously investigated in women with breast and ovarian
cancers (31, 32), suggesting that they correspond with survival
rates or chemotherapeutic sensitivity. Although the present study
was aimed at mRNA expression levels of genes related to DNA
DSB repair, faltering mRNA expression of these genes may
affect ovarian reserves in a manner similar to women with
BRCA germline mutations. It is believed that BRCA1-related
DNA DSB repair efficiency may be an important determinant
of oocyte aging in women (17). Researchers have found that
BRCA1 gene expression showed a significant age-related decline
in oocytes and that oocyte-specific knockdown of BRCA1
expression increases DSBs.
Endometriosis is a disease related to elevated oxidative
stress in the follicular environment, paracrine environment, and
systemically (33). Oxidative stress causes DNA damage (34).
Histone H2AX, one of several variants of the nucleosome core
histone H2A, becomes phosphorylated on Ser139 in response to
DSBs (γ-H2AX). Within seconds of DSB occurrence, γ-H2AX
foci appear at sites of DNA damage, which are detectable by
confocal microscopy, or immunohistochemistry in quantifying
DNA damage. Foci of γ-H2AX represent DSBs in a 1:1 ratio,
enabling sensitive quantitation of DSBs (35).
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FIGURE 3 | Endometrial mRNA expression of BRCA1, BRCA2, Rad51, and ATM in endometriosis group and in controls. *p < 0.05. Data are expressed as mean ±
SEM.
FIGURE 4 | Ovarian mRNA expression of BRCA1, BRCA2, Rad51, and ATM in endometriosis group and in controls. *p < 0.05, **p < 0.01. Data are expressed as
mean ± SEM.
In the present study, we found that occurrences of DNA
DSBs, as represented by γ-H2AX protein expression, increased
in endometrial, and ovarian endometrioma samples of patients
with endometriosis. However, two earlier immunohistochemical
studies have reported results contradictory to ours. In women
with endometriosis, persistence of proliferative markers in
eutopic endometrial cells seemed to be associated with
virtually complete loss of γ-H2AX (36); and endometrial cells
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FIGURE 5 | Correlation between serum anti-Müllerian hormone levels (AMH)
and ovarian BRCA1 expression in patients with endometriosis (Spearman’s
rho, 0.541; p = 0.030).
FIGURE 6 | Immunofluorescence staining of BRCA1 in eutopic endometrium
and ovarian tissue of patients with and without endometriosis. CTL-EM,
eutopic endometrium of patients without endometriosis; EMS-EM, eutopic
endometrium of patients with endometriosis; CTL-OV, Non-endometriotic
ovarian tissue; EMS-OV, ovarian endometriotic cyst.
from ectopic sites dysplayed immune-staining for proliferative
markers, with concomitant loss of the γ-H2AX staining in
ectopic endometriotic lesions of both human and baboon
endometriosis model (37). These differences may be due to the
differing characteristics of subjects selected for study. Although
all of our patients had advanced-stage endometriosis with
endometrioma(s), all stages of peritoneal endometriosis (I-IV)
were included. Moreover, immunnostains performed in the
latter study were confined to peritoneal endometriotic lesions.
Immunodetection of γ-H2AX is used to quantify DNA damage
in cells and tissues, and has diagnostic and prognostic value in
cancer. High phosphorylation levels are indicative of defective
DNA repair and genomic instability in premailignant lesions
and in tumors; and they are associated with higher-grade
malignancy and poor prognoses in various cancers, including
breast, colorectal, lung, and ovarian cancers, and melanoma (38)
as well as endometrial cancer (39).
In our experiments with in vitro cell cultures, we also
demonstrated that endometrial and ovarian tissues of patients
with endometriosis are more vulnerable to genotoxic stimuli,
showing an increased propensity for DNA damage compared
with controls. Following genotoxic exposure with H2O2, γ-
H2AX expression by endometrial stromal cells, and Ishkawa
cell line increased in tandem, whereas endometrial stromal cells
of control subjects were devoid of γ-H2AX expression, even
after H2O2 treatment. These findings may certainly stem from
impaired DNA DSB repair.
Although we did not directly demonstrate attenuated DNA
DSB repair or DSB repair mechanisms in ovarian follicles or
oocytes, we did establish that BRCA1 expression in ovarian
endometriotic tissue and serum AMH level (a marker of
ovarian reserve) correlated significantly. Diminished expression
of BRCA in ovarian endometrotic tissue is then indicative
of impaired DNA DSB repair and ultimately is attributable
to follicular damage. Given that endometriosis is associated
with oxidative stress locally and systemically and incite chronic
inflammation within the peritoneal cavity, heightened DNA
damages, and impairment of DNA repair in ectopic endometrial
tissue may mirror the status of ovarian follicles, both oocytes
and surrounding follicular cells. Finally, pathologic findings
akin to chemotherapy-induced ovarian damage (i.e., focal
fibrosis, vascular deficiency, and concomitant lowering of
follicular density) in women with endometriosis may attest
to microvascular and stromal damage. As documented in the
mouse ovary, doxorubicin insult initially induces DNA damage
in stroma, theca, and granulosa cells, followed by oocytic DNA
damage (40). Thus, DNA damage in adjacent somatic cells and
stroma also plays a role in decreased ovarian reserves.
Although gene expression patterns of endometrium might
be different according menstrual phase, we compared gene
expression patterns irrespective of menstrual phase. However,
their distribution in the present study was comparable between
the two groups. When we also compared mRNA expression of
BRCA1, BRCA2, Rad 51, and ATM between proliferative phase
and secretory phase endometrium using quantitative RT-PCR,
there were no significant differences in mRNA expressions of
BRCA1, BRCA2, Rad 51, and ATM between proliferative and
secretory phase endometrium (data were not shown).
Eutopic endometrium of women with endometriosis shows
fundamental differences compared with that of healthy control
(23). The eutopic and ectopic endometrium of women with
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endometriosis shares alterations that are not found in the eutopic
endometrium of women without endometriosis, corroborating
the idea that this altered endometrium in the peritoneal cavity
has the initial potential to develop endometriosis (41). In
the present study, we observed increased DNA damages and
impaired DNA DSB repair mechanism in eutopic endometrium
as well as ectopic endometrium. However, there were no
significant correlations between genes related to DNA DSB
repair in eutopic endometrium and AMH. Although it could
not be clearly explained, it may due to small sample size. On
the other hand, it may be explained as a direct consequence
of the different endocrine microenvironments such as the
peritoneal fluid and the intraovarian microenvironment
of ectopic endometrium and the intrauterine environment
in eutopic endometrium. Nonetheless, considering that
autocrine and paracrine effects following DNA damage,
findings of ectopic endometrium may be more important
than those of eutopic endometrium with respect to ovarian
reserve.
In the clinical characteristics, BMI was significantly lower in
endometriosis group compared with controls. Oxidative stress in
obesity poses a significant threat to DNA stability and integrity
as indicated by the growing number of investigations reporting a
positive correlation between markers of oxidative DNA damage
and increased adiposity (42). Obesity induces DNA damage in
hematopoietic stem cell transplant recipients that have been
treated by cyclophosphamide (43). Since there were significant
increases in DNA damages and impairment of genes related
DNA DSB repair in spite of protective effect of low BMI in
endometriosis group, the difference of BMI could not affect our
results.
In conclusion, we have determined that expression levels
of various genes implicated in DSB repair are diminished in
patients with endometriosis. In particular, BRCA1 expression
is decreased in both ovarian and endometrial tissues of such
patients and appears to correlate with AMH, a marker of ovarian
reserves. These findings indicate that impaired DSB repair is
a likely contributor to diminished ovarian reserves in women
with endometriosis. However, further studies will be necessary to
confirm the association between impairment of DNA DSB repair
and decreased ovarian reserve in this setting.
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